Notice for the Annual General Meeting of Novo Nordisk A/S
February 23 2021 - 2:02AM
Notice for the Annual General Meeting of Novo Nordisk A/S
Bagsværd, Denmark, 23 February 2021 – The
Annual General Meeting of Novo Nordisk A/S will be held
on: Thursday 25 March 2021 at 14:00 (CET)
Due to COVID-19, the Annual General Meeting is held as a fully
virtual meeting and shareholders will not be able to be physically
present at the meeting. Instead, shareholders will be able to
participate via an IT application and we encourage shareholders to
exercise their rights by submitting proxies or votes by
correspondence in advance of the Annual General Meeting.
Also, Novo Nordisk offers the possibility of viewing the Annual
General Meeting via live webcast on Novo Nordisk’s website.
Please refer to the notice for further information.
The notice for the Annual General Meeting, including Appendix:
Candidates for the Board of Directors, is enclosed.
BOARD OF DIRECTORS All board members elected by
the Annual General Meeting are up for election. Brian Daniels and
Liz Hewitt have decided not to seek re-election.
The Board of Directors proposes re-election of the following
board members elected by the Annual General Meeting: Helge Lund
(chair), Jeppe Christiansen (vice-chair), Laurence Debroux, Andreas
Fibig, Sylvie Grégoire, Kasim Kutay and Martin Mackay.
The Board of Directors proposes the election of Henrik Poulsen
as a new member of the Board. Mr Poulsen served as CEO and
president of the renewable energy company Ørsted A/S, Denmark, in
the period 2012-2020. Prior to that Mr Poulsen was CEO and
president of the telecommunication company TDC A/S, Denmark. From
2007-2008 Mr Poulsen served as operating executive of Kohlberg
Kravis Roberts & Co. in the UK preceded by executive roles with
the LEGO group, Denmark, in the period 1999-2006. The Board of
Directors proposes the election of Henrik Poulsen to the Board of
Directors primarily because of his extensive executive and board
experience in large international companies, significant financial
knowledge and in-depth knowledge of strategy, transformation,
innovation, and mergers and acquisitions.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive
change to defeat diabetes and other serious chronic diseases such
as obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines and working to prevent and ultimately cure disease.
Novo Nordisk employs about 45,000 people in 80 countries and
markets its products in around 170 countries. Novo Nordisk's B
shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are
listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Twitter, LinkedIn,
YouTube.
Further information
Media: |
|
|
Mette Kruse
Danielsen |
+45 3079 3883 |
mkd@novonordisk.com |
Michael Bachner
(US) |
+1 609 664
7308 |
mzyb@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann
Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
Valdemar Borum
Svarrer |
+45 3079 0301 |
jvls@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
Mark Joseph
Root |
+45 3079 4211 |
mjhr@novonordisk.com |
Kristoffer Due
Berg (US) |
+1 609 235
2989 |
krdb@novonordisk.com |
Company announcement No 15 / 2021
- CA210223_AGM_Notice_combined
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jul 2023 to Jul 2024